{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-000540","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.067739+00:00","generated_at":"2026-06-06T14:50:43.809804+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Sunshine Biopharma appoints new COO and Chief Development Officer at annual meeting","bullets":["Marc Beaudoin appointed COO; Malek Chamoun appointed Chief Development Officer, effective Jan 25, 2024.","Dr. Abderrazzak Merzouki moved from COO to Chief Science Officer.","Camille Sebaaly continues as CFO/Secretary; Dr. Steve Slilaty continues as President/CEO.","Malek Chamoun is also President of subsidiary Nora Pharma Inc., acquired in Oct 2022.","Beaudoin has 10 years at Sandoz Canada; Chamoun is a CPA with HEC Montreal degree."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-000540","json":"https://secwatch.observer/filing/0001683168-24-000540.json","markdown":"https://secwatch.observer/filing/0001683168-24-000540.md","text":"https://secwatch.observer/filing/0001683168-24-000540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:50:43.809804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58c98b497b","claim":"Dr. Abderrazzak Merzouki was elected as Chief Science Officer at Sunshine Biopharma Inc..","evidence_excerpt":"Previously, Dr. Merzouki had held the position of Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chief Science Officer"}],"fact_type":"executive_change"},{"claim_id":"b36ce4a45e","claim":"Malek Chamoun was appointed as Chief Development Officer at Sunshine Biopharma Inc..","evidence_excerpt":"Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"f7c1966076","claim":"Marc Beaudoin was appointed as Chief Operating Officer at Sunshine Biopharma Inc..","evidence_excerpt":"Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}